Health & Fitness
Health and Fitness
Health and Fitness
Wed, May 25, 2011
Tue, May 24, 2011 Derma Sciences to Hold Conference Call Tomorrow, May 25 to Discuss 24-Week Data from Phase 2 DSC127 Trial in Diabetic Foot Ulce
PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, will issue a news release announcing 24-week data from its Phase 2 trial with DSC127 in diabetic foot ulcers at 7:00 a.m. Eastern time Wednesday, May 25 and will hold a conference call to discuss those results at 11:00 a.m. Eastern time that same day.
To participate in the conference call, from the U.S. please dial (888) 563-6275 and from outside the U.S. please dial (706) 634-7417. All listeners should provide passcode 67127770. Individuals interested in listening to the live conference call via the Internet may do so by logging onto the Companya™s website, [ www.dermasciences.com ]. Slides summarizing the clinical data will be available at [ dermasciences.com/dsc127slides ].
Following the completion of the conference call, a replay will be available through June 1, 2011, and can be accessed by dialing (800) 642-1687 from the U.S. or (706) 645-9291 from outside of the U.S. All listeners should provide passcode 67127770. The webcast will also be available on the Companya™s website for 30 days.
About Derma Sciences, Inc
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace, traditional dressings, advanced wound care dressings, and pharmaceutical wound care products. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention. Derma Sciences has successfully completed a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. For more information please visit [ www.dermasciences.com ].
